Cap-Independent Translation in Hematological Malignancies.
Cap-Independent Translation in Hematological Malignancies.
复制标题
DOI：
10.3389/fonc.2015.00293
复制
发表时间：
2015
影响因子：
4.7
通讯作者：
Willis AE
中科院分区：
文献类型：
--
作者：
Horvilleur E;Wilson LA;Bastide A;Piñeiro D;Pöyry TA;Willis AE
血液学恶性肿瘤是由血细胞祖细胞引起的一组异质性疾病。尽管许多与血癌相关的基因都含有内部核糖体进入位点（IRESes），但很少有研究关注帽独立翻译在白血病和淋巴瘤中的作用。IRES反式作用因子的表达也可以改变，有趣的是，在某些类型的白血病中发现，从“费城”染色体表达的BCL-ABL1融合蛋白可以调节其中的几种。涉及c-Myc IRES和帽独立翻译并导致多发性骨髓瘤化疗耐药的机制强调了帽独立翻译在血癌中的作用，需要做更多的工作来阐明已知IRESes在病理和化疗反应中的作用。
Hematological malignancies are a heterogeneous group of diseases deriving from blood cells progenitors. Although many genes involved in blood cancers contain internal ribosome entry sites (IRESes), there has been only few studies focusing on the role of cap-independent translation in leukemia and lymphomas. Expression of IRES trans-acting factors can also be altered, and interestingly, BCL-ABL1 fusion protein expressed from “Philadelphia” chromosome, found in some types of leukemia, regulates several of them. A mechanism involving c-Myc IRES and cap-independent translation and leading to resistance to chemotherapy in multiple myeloma emphasize the contribution of cap-independent translation in blood cancers and the need for more work to be done to clarify the roles of known IRESes in pathology and response to chemotherapeutics.